Vertex stock price target raised to $550 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.
FDA approves drug from Boston-based company to treat pain without opioid effects
The drug, suzetrigine, made by Boston-based Vertex Pharmaceuticals and to be sold as Journavx, works only on nerves outside ...
The American Journal of Managed Care3d
Suzetrigine: First-in-Class Nonopioid Pain Therapy Is Approved by FDA
Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...
BioSpace3d
FDA Approves Vertex’s Journavx as First New Pain Drug in Decades
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
The Pharma Letter3d
FDA nod for Vertex’ non-opioid pain drug Journavx
Shares of US drugmaker Vertex Pharmaceuticals jumped 8.4% to $475.00 in after-hours trading yesterday after it announced that ...
FDA green lights new painkiller
The new drug type targets pathways in the peripheral nervous system before pain signals reach the brain, potentially lowering ...
FiercePharma4d
Vertex scores FDA nod for long-awaited non-opioid pain reliever Journavx
Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...
FDA approves new type of non-opioid pain medication, 1st of its kind in more than 20 years
The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to treat moderate to severe acute pain. The drug, called Journavx (suzetrigine) ...
Eagle-Tribune4d
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Chromocell Therapeutics (NYSE:CHRO) Stock Price Down 10.6% – Time to Sell?
Chromocell Therapeutics Co. (NYSE:CHRO – Get Free Report)’s share price traded down 10.6% during mid-day trading on Wednesday . The company traded as low as $2.11 and last traded at $2.20. 105,552 ...
pharmaphorum11d
Tris cues up filing for non-opioid pain drug on phase 3 win
The new data comes from the phase 3 ALLEVIATE-1 trial, which compared cebranopadol to placebo for the management of ...